Incyte Strengthens Leadership Team with Key Senior Appointments to Drive Long-Term Growth Incyte has announced a series of strategic appointments to its senior management team, reinforcing its leadership structure as…
Artesia General Hospital Leverages Ambient AI to Transform Rural Healthcare Delivery ARTESIA,General Hospital (AGH), a leading healthcare provider serving southeastern New Mexico, is taking a major step forward in modernizing…
Medpace Conference Call Scheduled for April 23 with Webcast and Replay Available on Investor Website Medpace Holdings, Inc. has announced the timing for the release of its financial results for…
Johnson & Johnson Secures U.S. Food and Drug Administration Approval for TECNIS PureSee Intraocular Lens, Expanding Vision Care Options for U.S. Cataract Patients Johnson & Johnson announced U.S. Food and Drug…
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan Curatis Holding AG and Neupharma Co., Ltd. a…
Fierce Healthcare Names SpotitEarly a “Fierce 15” Company of 2026 SpotitEarly, a multi-cancer early detection startup that uses AI and trained canines to identify cancer odor signatures in breath samples,…
NRC Health Announces $60 Million Share Repurchase Authorization National Research Corporation, doing business as NRC Health, has announced that its Board of Directors has approved a new stock repurchase program…
MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era MindWalk Holdings Corp. a bio-native AI company, today announced B Cell Llama™, a platform…
Savara Provides Regulatory Update on MOLBREEVI Development Program for Autoimmune Pulmonary Alveolar Proteinosis Savara clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases, has announced a significant regulatory…
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia DiaMedica Therapeutics Inc. a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal…
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM) Affinia Therapeutics an innovative gene therapy company with a pipeline…
Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting Pulse Biosciences, Inc. developer of the novel nPulse™ technology using…